New ray of hope for psychosis in parkinson’s: Pimavanserin
Journal Title: International Journal of Medical and Dental Sciences - Year 2016, Vol 5, Issue 2
Abstract
Parkinson’s disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine & Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson’s disease psychosis in a dose of 34 mg.
To Compare the Efficacy and Complication of Nasal Prongs vs Nasal Mask CPAP in Neonates
Background: CPAP refers to the application of positive pressure to the airway of a spontaneously breathing infant throughout the respiratory cycle. Objectives: To study the clinical pattern of CPAP in neonate Method: T...
Neonatal Sepsis-Culture Positive Sepsis Vs Clinical Sepsis
Background: The incidence of sepsis is increasing globally, with high morbidity and mortality. Diagnosis of neonatal sepsis is still a clinical and laboratory challenge. Though blood culture is gold standard, it sometime...
Tobacco habits among the youth in Bangalore city, India: A survey
Background: Oral cancer is globally recognized as a major oncological problem. Tobacco in the form of chewing/smoking is one of the main etiological factors of oral cancer. Tobacco habits are usually initiated during ado...
Breast Feeding Practices in Infants of Rural Western Uttar Pradesh Region of India
Background: Breastfeeding is one of the most effective ways to ensure child health and survival. But globally only less than 40% of infants under six months of age are exclusively breastfed. Adequate breastfeeding counse...
Clinical Profile of Subclinical Hypothyroidism:A Retrospective Study
Background: Subclinical hypothyroidism occurs due to an under functioning thyroid gland and presents with varied symptoms and signs. Thyroid disorders are common in Indian population and the prevalence of subclinical hyp...